Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.

Related Keywords

Utah ,United States ,Texas ,San Antonio ,France ,University Of Texas ,Paris ,France General ,American ,Bristol Myers Squibb ,Neil Newman ,Thierry Andre ,Mark Lewis ,Drug Administration ,University Of Texas Health Science Center ,Sorbonne University ,Clinical Oncology Gastrointestinal Cancers ,Texas Health Science Center ,Intermountain Healthcare ,Medscape Medical News ,Colorectal Cancer ,Colorectal Cancer Crc ,Chemotherapy ,Biologic Therapy ,Iologics ,Metastatic Colorectal Cancer ,Metastatic Crc ,Crc ,Etastatic Colorectal Cancer Mcrc ,Microsatellite Instability High ,Micro Satellite Instability High ,Msi H ,Immunotherapy ,Microsatellite Instability ,Si ,Breast Cancer ,Alignant Breast Neoplasm ,Breast Carcinoma ,